Friday, September 12, 2025

Cybin: Eight Capital Initiates With $8.15 Price Target

Earlier this week, Eight Capital launched coverage on a basket of psychedelic companies. This comes after they produced an industry primer during the summer months. The second company on this list is Cybin Inc (NEO: CYBN), which they have given an C$8.15 12-month price target and buy rating.

Cybin currently has 6 analysts covering the stock with an average 12-month price target of C$9.53, or a 230% upside. Out of the 6 analysts, 2 have strong buy ratings and the other 4 have buy ratings. The street high comes in at $15 from Stifel-GMP while the lowest price target is C$7.

Eight Capital says that since Cybin went public late last year, the company has developed and further diversified its pipeline to have multiple assets towards clinical stages, commenting, “The Company looks poised to take its orally-delivered psilocybin formulation.” They also expect a number of catalysts going into the second half of this year and the first half of 2022.

The first point Eight Capital makes is that the company has done a good job at derisking itself as its working towards a commercial distribution of oral psilocybin, “that stands out as a differentiated route of delivery for this asset, which could translate to favourable safety and efficacy relative to other approaches.” They add that the readout from Compass Pathways on their Ph2b psilocybin pill formulation expected by year-end should give a good baseline as well as extra confidence in Cybin’s trial.

The next point from Eight Capital, is that the company has secured multiple solid partners, with their partnership with Catalent for use of its orally dissolving tablet. Additionally, they have partnership agreements with Covance and Kernal for different technology. The firm also has a strong balance sheet when compared to peers. The company has $99 million in pro-forma cash, which is expected to fund the companies trials through Eight Capital’s forecast period.

The last highlight made by Eight Capital is the potential for a collaboration with a large pharmaceutical company. They say that the 2019 FDA approval of Johnson and Johnson’s psychedelic-based treatment for relevant mental health conditions makes it clear that the “big pharma” has the go-ahead to touch these assets. Eight Capital writes, “we view an eventual take-out or partnership/collaboration opportunities with pharmaceutical giants as a natural progression of events.”

Below you can see the catalysts Eight Capital is watching for.


Information for this briefing was found via Sedar and Refinitiv. The author has no securities or affiliations related to this organization. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security. The author holds no licenses.

Video Articles

Avino Q2 Earnings: Steady As She Goes

MEG Energy: Cenovus Comes In With $7.9 BILLION Offer

Orla Mining Q2 Earnings: Musselwhite Changes Everything

Recommended

Northern Superior Expands Philibert With 350 Metre Step Out Testing 1.10 g/t Gold Over 25.5 Metres

Goliath Resources Hits 18.58 g/t Gold Over 5.00 Metres At Surebet

Related News

BMO Lowers Maple Leaf Foods’ Earnings Estimates On Expected Headwinds

Maple Leaf Foods (TSX: MFI) is expected to report its second-quarter financial results on August...

Saturday, July 9, 2022, 03:17:00 PM

Analysts Downgrade Lundin Mining En Masse After Guidance Update

On November 30th, Lundin Mining (TSX: LUN) provided their long-awaited three-year production guidance for 2021...

Wednesday, December 2, 2020, 12:24:00 PM

Village Farms: Analysts Expect Q3 Revenues To Hit US$68.7 Million

Village Farms International (TSX: VFF) announced that they will be reporting their third quarter financials...

Monday, November 8, 2021, 05:17:00 PM

Facebook Blows Analyst Expectations Away With Strong Results

Facebook Inc (NASDAQ: FB) opened 8% higher Thursday morning, reaching record highs and closing in...

Saturday, May 1, 2021, 03:34:00 PM

Canaccord Slightly Lowers SSR Mining’s Price Target Off Back Of 2022 Guidance

Recently, SSR Mining Inc. (TSX: SSRM) announced full-year 2021 production results, a three-year outlook, and...

Friday, February 11, 2022, 05:10:00 PM